Skip to main content
Premium Trial:

Request an Annual Quote

Takeda, University of Kyoto Partner on CNS Drug Targets and Biomarkers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical and Kyoto University today announced a five-year deal focused on the development of new central nervous system-acting drugs for obesity and schizophrenia.

Under the terms of the deal, the university and Takeda will seek to identify new drug targets and biomarkers for the diseases. Medical research aimed at developing new drugs will also be conducted "by utilizing not only findings from basic research and clinical data accumulated at the Graduate School of Medicine and the University Hospital, but also its worldwide networks," the partners said.

Financial and other terms were not disclosed.

In a statement Shigenori Ohkawa, chief scientific officer for Takeda, said that "Through the close partnership on research and development, we expect that we weill be able to create innovative drugs for obesity and schizophrenia where there is a high unmet need for patients."

In November, Takeda and Sage Networks announced a partnership also directed at CNS drugs. Last month, the drug firm, Sanford-Burnham Medical Research Institute and Florida Hospital said they would be using genomic and metabolite profiling as part of an effort aimed at developing new therapies for obesity.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.